FDA Warns of Experimental Procedure for Autonomic Dysfunction
The US FDA is warning physicians and patients for the second time to be aware of an experimental procedure that is being promoted as a treatment in autonomic dysfunction.
The US FDA is warning physicians and patients for the second time to be aware of an experimental procedure that is being promoted as a treatment in autonomic dysfunction.
The United States Preventive Services Task Force failed to recommend routine screening for obstructive sleep apnea in asymptomatic adults.
There is a need for better assessment of autonomic symptoms in pediatric headache patients.
“Clinicians should not ignore migraine when treating MS/P in patients with MDD.”
Stroke preventive measures should be considered in women with a history of migraine headache.
Botox treatment led to significant improvement in the intensity and frequency of migraine.
Ultimately, the trial was stopped early for futility, as an interim analysis suggested that there would be no significant difference in benefit for the preventive medications vs placebo on migraine headache frequency.
Ziprasidone may be an effective, fast-acting treatment for status migrainosus.
Because the increased cytokine levels in the acute phase of herpes zoster are assumed to be a potential mechanism for inducing PHN, the early suppression of these cytokines by LLLT may help prevent the development of PHN.
At post-treatment examination, participants in the exercise group demonstrated a significantly greater improvement in general fatigue, physical fatigue, and mental fatigue, compared to the active control group.